Imugene’s products are likely to sell into large and growing markets. In the case of the pig
and chicken products a key driver is the move away from medicated feeds while the flea vaccine
project may be a beneficiary of the large sums of money people lavish on their companion
animals.
�� We value Imugene at 52 cents per fully diluted share base case, and $1.70 per fully diluted
share on a ‘Speculative If Everything Works’ case. Our share price target of $1.11 is a midpoint
of these two figures.
thirty mill deal clinched by aussie biotech, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |